ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.
Also NCI prostate SPOREs plan biospecimen bank.
NCI advisors seek comment on clinical trials system, until Jan. 15.
NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.
Dept. of Defense opens program announcements for prostate cancer research.
Children’s Cancer Research Institute at UT Health Science Center recruits faculty.
Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.
December issue of Business & Regulatory Report included (an additional 8 pages of industry news).
Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- FDA issues warning letter to ImmunityBio over misleading claims about cancer drug
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants









